Helga Bernhard
Overview
Explore the profile of Helga Bernhard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
2084
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Derigs P, Schubert M, Dreger P, Schmitt A, Yousefian S, Haas S, et al.
Leukemia
. 2024 Aug;
38(11):2419-2428.
PMID: 39192036
Third-generation chimeric antigen receptor T cells (CARTs) for relapsed or refractory (r/r) chronic lymphocytic leukemia (CLL) may improve efficacy compared to second-generation CARTs due to their enhanced CAR design. We...
2.
Berghaus N, Schreiner S, Poos A, Raab M, Goldschmidt H, Mai E, et al.
FEBS J
. 2023 Apr;
290(17):4256-4267.
PMID: 37097223
Light chain amyloidosis (AL) is one of the most common forms of systemic amyloidosis and is caused by the deposition of insoluble fibrils derived from misfolded and aggregated immunoglobulin light...
3.
Moehler M, Folprecht G, Heinemann V, Holch J, Maderer A, Kasper S, et al.
Int J Cancer
. 2021 Nov;
150(8):1341-1349.
PMID: 34807464
Metastatic colorectal cancer (mCRC) patients with liver-limited disease (LLD) have a chance of long-term survival and potential cure after hepatic metastasectomy. However, the appropriate postoperative treatment strategy is still controversial....
4.
Mai E, Miah K, Bertsch U, Durig J, Scheid C, Weisel K, et al.
Leukemia
. 2021 Nov;
35(12):3636.
PMID: 34785794
No abstract available.
5.
Klein E, Tichy D, Salwender H, Mai E, Duerig J, Weisel K, et al.
Cancers (Basel)
. 2021 Oct;
13(19).
PMID: 34638344
We investigated the prognostic impact of time-dependent serum free light chain ratio (FLCr) normalization in 590 patients with secretory multiple myeloma (MM) during first-line treatment within the German-Speaking Myeloma Multicenter...
6.
Baertsch M, Mai E, Hielscher T, Bertsch U, Salwender H, Munder M, et al.
Blood Cancer J
. 2021 Jan;
11(1):1.
PMID: 33414374
Lenalidomide (LEN) maintenance (MT) post autologous stem cell transplantation (ASCT) is standard of care in newly diagnosed multiple myeloma (MM) but has not been compared to other agents in clinical...
7.
Schimanski C, Kasper S, Hegewisch-Becker S, Schroder J, Overkamp F, Kullmann F, et al.
Oncoimmunology
. 2020 Sep;
9(1):1806680.
PMID: 32923171
Abbreviations: AE: adverse event; CP: cyclophosphamide; CRC: colorectal cancer; CT: computed tomography; ECOG: Eastern Cooperative Oncology Group; FU: follow-up; HR: hazard ratio; IHC: immunohistochemical staining; ITT: intention-to-treat; DSMB: Data Safety...
8.
Mai E, Miah K, Bertsch U, Durig J, Scheid C, Weisel K, et al.
Leukemia
. 2020 Jul;
35(3):809-822.
PMID: 32684633
Intensive upfront therapy in newly-diagnosed multiple myeloma (MM) including induction therapy (IT), high-dose melphalan (MEL200), and autologous blood stem cell transplantation (ASCT) followed by consolidation and/or maintenance is mostly restricted...
9.
Schmitz C, Rekowski J, Muller S, Hertenstein B, Franzius C, Ganser A, et al.
Hematol Oncol
. 2020 Feb;
38(3):244-256.
PMID: 32067259
The prospective randomized Positron Emission Tomography (PET)-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL) trial was designed to test the ability of interim PET (iPET) to direct therapy. As reported previously,...
10.
Goldschmidt H, Mai E, Durig J, Scheid C, Weisel K, Kunz C, et al.
Leukemia
. 2020 Feb;
34(7):1853-1865.
PMID: 32034285
The MM5 trial aimed at demonstrating a progression-free survival (PFS) difference in continued vs. response-adapted (in case of complete response, CR) lenalidomide (LEN) maintenance therapy (MT) in newly diagnosed, transplant-eligible...